Meclinas
- Address
- Stationsstraat 102-108, 2800 Mechelen, Belgium
Meclinas Clinical Research Center
Meclinas is a comprehensive medical research center conducting advanced clinical trials across multiple therapeutic areas. The center demonstrates particular expertise in evaluating novel therapeutic interventions for complex chronic conditions, ranging from cardiovascular and renal disorders to neuropsychiatric conditions and respiratory diseases.
- Mental health disorders including schizophrenia with cognitive impairment and major depressive disorder with anhedonia
- Chronic kidney disease management with a focus on hypertension control and cardiovascular outcomes
- Respiratory conditions including uncontrolled asthma and vaccine development for respiratory syncytial virus
- Combination therapy approaches and adjunctive treatment strategies for improved patient outcomes
The research center specializes in phase III clinical trials and long-term safety extension studies, with particular emphasis on evaluating both efficacy and safety profiles of investigational therapies. Meclinas conducts studies examining adjunctive pharmacotherapy for treatment-resistant conditions, novel interventions for cognitive impairment in schizophrenia, and innovative approaches to managing chronic kidney disease with concurrent hypertension. The center also participates in vaccine immunogenicity studies, including co-administration trials for RSV and COVID-19 vaccines in older adult populations, demonstrating their commitment to preventive medicine and infectious disease research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Eli Lilly & Co.2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Meclinas
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjunctive Aticaprant and Antidepressant Therapy for Relapse Prevention in Major Depressive Disorder with Moderate-to-Severe Anhedonia: A Randomized, Double-Blind Study | Janssen Cilag International | Phase III | Not Recruiting | Dec 2024 | Feb 2025 |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE | 2 | Unknown | 2025-08-28 | 2025-10-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.